Showing 25,421 - 25,440 results of 53,759 for search '(( 5 ((non decrease) OR (mean decrease)) ) OR ( 50 ((mg decrease) OR (a decrease)) ))', query time: 1.37s Refine Results
  1. 25421

    Monoterpenoids (thymol, carvacrol and S-(+)-linalool) with anesthetic activity in silver catfish (Rhamdia quelen): evaluation of acetylcholinesterase and GABAergic activity by A.E. Bianchini (6515891)

    Published 2019
    “…AChE activity was increased in the brain of fish at 50 mg/L carvacrol and 100 mg/L thymol, and decreased in the muscle at 100 mg/L carvacrol. …”
  2. 25422
  3. 25423
  4. 25424
  5. 25425
  6. 25426
  7. 25427
  8. 25428
  9. 25429
  10. 25430
  11. 25431
  12. 25432

    Data Sheet 2_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

    Published 2025
    “…</p>Study design<p>In the phase Ib study, a total of 50 participants with T2DM were enrolled and randomly assigned to the 0.5 mg BID, 1 mg BID, 2 mg BID, 1 mg QD, and 2 mg QD dose groups, with a 4:1 random allocation within each group to receive either the SY-009 capsule or placebo. …”
  13. 25433

    Data Sheet 1_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

    Published 2025
    “…</p>Study design<p>In the phase Ib study, a total of 50 participants with T2DM were enrolled and randomly assigned to the 0.5 mg BID, 1 mg BID, 2 mg BID, 1 mg QD, and 2 mg QD dose groups, with a 4:1 random allocation within each group to receive either the SY-009 capsule or placebo. …”
  14. 25434
  15. 25435

    Table_1_Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs.pdf by Gabriel A. Garcia (13172817)

    Published 2022
    “…Epileptic seizure frequency decreased across the population from a mean of 8.0 ± 4.8 during placebo treatment to 5.0 ± 3.6 with CBD/CBDA-rich hemp extract (P = 0.02). …”
  16. 25436
  17. 25437

    Data_Sheet_1_A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes.DOC... by Azam Doustmohammadian (8488608)

    Published 2022
    “…<p>The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg sitagliptin (n = 60) or the placebo (n = 60) for 56 weeks and lifestyle modification in both groups. …”
  18. 25438
  19. 25439
  20. 25440